Danaher Co. (NYSE:DHR) Shares Purchased by Sunflower Bank N.A.

Sunflower Bank N.A. grew its stake in shares of Danaher Co. (NYSE:DHR) by 9.5% during the fourth quarter, Holdings Channel reports. The firm owned 1,530 shares of the conglomerate’s stock after purchasing an additional 133 shares during the period. Sunflower Bank N.A.’s holdings in Danaher were worth $351,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the third quarter worth $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher in the third quarter valued at about $50,000. Darwin Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at approximately $55,000. Finally, Modus Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $56,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.0 %

DHR traded up $4.76 during trading hours on Monday, reaching $239.83. 3,208,265 shares of the stock traded hands, compared to its average volume of 2,915,061. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a market cap of $173.22 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s fifty day simple moving average is $235.67 and its two-hundred day simple moving average is $253.73.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, analysts forecast that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Robert W. Baird lowered their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Raymond James dropped their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.